Deciphera pharmaceuticals, inc. (DCPH)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Revenues

62

0

0

25,000

0

-

0

-

0

0

0

0

0

Operating expenses:
Research and development

51,388

46,636

40,374

34,811

35,789

27,356

20,630

17,976

16,925

15,658

9,751

8,446

5,659

Selling, general, and administrative

23,936

-

-

-

13,236

-

-

-

-

-

-

-

-

Selling, general, and administrative

-

-

17,979

13,164

-

6,474

5,259

4,453

5,026

4,680

2,430

2,244

2,067

Total operating expenses

75,324

70,373

58,353

47,975

49,025

33,830

25,889

22,429

21,951

20,338

12,181

10,690

7,726

Loss from operations

-75,262

-70,373

-58,353

-22,975

-49,025

-33,830

-25,889

-22,429

-21,951

-20,338

-12,181

-10,690

-7,726

Other income (expense):
Interest and other income, net

2,455

3,169

2,174

1,540

1,654

1,551

1,475

760

543

449

166

89

42

Interest expense

0

12

17

25

13

20

21

21

22

23

23

24

25

Total other income (expense), net

2,455

3,157

2,157

1,515

1,641

1,531

1,454

739

521

426

143

65

17

Net loss

-72,800

-67,260

-56,196

-21,460

-47,384

-32,345

-24,435

-21,690

-21,430

-19,928

-12,038

-10,625

-7,709

Net loss per share—basic and diluted (in dollars per share)

-1.36

-1.39

-1.28

-0.56

-1.25

-0.86

-0.65

-0.65

-0.66

-0.38

-1.04

-0.91

-0.66

Weighted average common shares outstanding—basic and diluted (in shares)

53,567

51,415

43,803

38,200

38,057

37,746

37,654

33,567

32,594

32,289

11,626

11,626

11,626

Comprehensive loss:
Net loss

-72,800

-67,260

-56,196

-21,460

-47,384

-32,345

-24,435

-21,690

-21,430

-

-

-

-

Other comprehensive income (loss):
Unrealized gains (losses) on marketable securities

652

50

-114

154

21

-

0

-

-

-

-

-

-

Total other comprehensive income (loss)

652

50

-114

154

21

-

0

-

-

-

-

-

-

Total comprehensive loss

-72,155

-67,166

-56,310

-21,306

-47,363

-32,299

-24,435

-21,690

-21,430

-

-

-

-